MedPath

Safety and Effectiveness of a Combination Anti-HIV Drug Treatment

Phase 4
Completed
Conditions
HIV Infections
Registration Number
NCT00005018
Lead Sponsor
Glaxo Wellcome
Brief Summary

The purpose of this study is to see if it is safe and effective to give HIV-positive patients a combination of anti-HIV drugs (abacavir \[ABC\] plus efavirenz \[EFV\] plus didanosine \[ddI\]) with and without hydroxyurea (HU).

Detailed Description

Patients are randomized into one of two treatment arms: ABC/EFV/ddI or ABC/EFV/ddI/HU. In the second treatment arm, patients are further randomized to receive HU beginning at Baseline, when ABC/EFV/ddI is started, or at Week 8. Delaying HU may help offset the cytopenic effect of HU, as reflected in a blunted CD4 cell response. Patients are stratified according to their screening plasma HIV-1 RNA level (400 to 10,000 copies/ml and more than 10,000 to 100,000 copies/ml). Participants in the study receive study-related exams, lab tests, and study medications at no cost over the 48-week treatment period. The safety and effectiveness of the non-protease inhibitor rescue therapy is evaluated routinely by measuring viral load and the CD4 cell count, as well as the side effects caused by the medications. All of the medications are approved by the FDA and are not considered investigational.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
150
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (23)

East Bay AIDS Ctr

🇺🇸

Berkeley, California, United States

Altamed Medical Health Services

🇺🇸

Los Angeles, California, United States

Gary Richmond MD

🇺🇸

Fort Lauderdale, Florida, United States

Burnside Clinic

🇺🇸

Columbia, South Carolina, United States

Univ of Texas / Thomas Street Clinic

🇺🇸

Houston, Texas, United States

St Lukes Medical Group

🇺🇸

San Diego, California, United States

Univ of Miami School of Medicine

🇺🇸

Miami, Florida, United States

Univ of Nebraska Medical Ctr

🇺🇸

Omaha, Nebraska, United States

Univ of NC Infectious Diseases

🇺🇸

Wilmington, North Carolina, United States

Univ of Kentucky Med Ctr

🇺🇸

Lexington, Kentucky, United States

Boston Med Ctr / Evans - 556

🇺🇸

Boston, Massachusetts, United States

Pacific Oaks Research

🇺🇸

Beverly Hills, California, United States

Beth Israel Med Ctr

🇺🇸

New York, New York, United States

Univ of Texas Med Branch

🇺🇸

Galveston, Texas, United States

Saint Josephs Comprehensive Research Institute

🇺🇸

Tampa, Florida, United States

CRI of New England

🇺🇸

Brookline, Massachusetts, United States

Pacific Horizons Med Group

🇺🇸

San Francisco, California, United States

Northstar Med Clinic

🇺🇸

Chicago, Illinois, United States

Univ of North Carolina / Infectious Disease Division

🇺🇸

Chapel Hill, North Carolina, United States

Saint Luke's - Roosevelt Hosp Ctr

🇺🇸

New York, New York, United States

Hampton Roads Med Specialists

🇺🇸

Hampton, Virginia, United States

Anderson Clinical Research Inc

🇺🇸

Reading, Pennsylvania, United States

Miriam Hosp

🇺🇸

Providence, Rhode Island, United States

© Copyright 2025. All Rights Reserved by MedPath